Atul Sobti, boss of Ranbaxy, an Indian generics firm bought last year by Novartis, a Japanese pharmaceutical giant, offers a different reason for scepticism.
去年被日本制药公司Novartis买下的印度非专利药品公司Ranbaxy的经理Atul Sobti却对这种怀疑给出了不同的原因。
Countries fear that pharmaceutical companies will use unfair tactics, really, every trick in the book, to reduce competition from lower-priced generics.
国家担心，制药公司会利用不公平的手法，真正是书本上的每一个把戏，来降低价格较低的非专利药的竞争性。
Kathleen Jaeger of America's Generic Pharmaceutical Association adds that branded firms try to extend their lucrative monopolies by filing less rigorous secondary patents designed “to block generics”.
美国通用药物协会的KathleenJaeger补充说很多品牌药公司制作大量的文件申请专利分案“以阻碍仿制药”。
Like many other emerging pharmaceutical sectors in Asia, the South Korean pharmaceutical industry has concentrated most of its efforts in generics.
如同亚洲其它新兴制药部门一样，韩国制药工业已把主要精力放在了非专利药上。
The generics market has always been the bread and butter of the Indian pharmaceutical manufacturing industry. However, since 2003 the global generics market has been experiencing a downward trend.
仿制药市场一直是的印度制药工业的天下，然而，自2003年全球仿制药市场已经正在呈现下降的趋势。
The big pharmaceutical companies are also struggling to refill their product pipelines with new offerings as their blockbuster drugs' patents expire and patients switch to generics.
由于大型制药公司的重点产品许多面临专利过期，患者纷纷转向非专利药，这些公司还面临要不断开发新药品的任务。
The big pharmaceutical companies are also struggling to refill their product pipelines with new offerings as their blockbuster drugs' patents expire and patients switch to generics.
由于大型制药公司的重点产品许多面临专利过期，患者纷纷转向非专利药，这些公司还面临要不断开发新药品的任务。
应用推荐